{"id":"W2890388049","doi":"10.1200/jco.2017.35.15_suppl.3529","title":"Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Cancer; Oncology; Combination therapy; Irinotecan; Gastroenterology; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007834391,0.001424695,0.001876338,0.0004620049,0.0003297806,0.0006958154,0.0005998213,0.0009327733,0.003832942],"category_scores_gemma":[0.0004579142,0.0006073299,0.0009668781,0.0004039788,0.0006542572,0.0006245351,0.0002910572,0.002381709,0.0008245073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008061006,"about_ca_system_score_gemma":0.001232072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001223076,"about_ca_topic_score_gemma":0.003296066,"domain_scores_codex":[0.9997968,0.00008035055,0.000009537975,0.00004218582,0.00002159212,0.00004954055],"domain_scores_gemma":[0.9997503,0.00002502999,0.00005109361,0.0000230686,0.00001959165,0.0001309515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6275079,0.1254152,0.006714032,0.001426683,0.001585198,0.0004461524,0.000404955,0.003841117,0.1196642,0.0004190533,0.004638908,0.1079366],"study_design_scores_gemma":[0.3375153,0.6403554,0.009390566,0.00004352026,0.0005079145,0.0003595322,0.00007087478,0.001278479,0.007352959,0.0001899318,0.00291133,0.00002409352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907613,0.002178434,0.0005310341,0.0003637441,0.00009414824,0.003504817,0.001075092,0.0001048384,0.001386481],"genre_scores_gemma":[0.9881465,0.002004274,0.001777093,0.0005185032,0.00008187647,0.002499834,0.002047578,0.00003045527,0.002893735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003832942,"threshold_uncertainty_score":0.01282245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3085729750230846,"score_gpt":0.5868428381078282,"score_spread":0.2782698630847436,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}